Latest news

15 May 2019 News
Tumor-targeting protein could advance personalized cancer therapy
9 May 2019 Brain and neurologic
Novel drug could be world’s first treatment for a pediatric brain cancer
1 May 2019 Breast
ESMO Breast Cancer 2019: should HER2-positive breast cancer treatment de-escalation be personalized?
30 Apr 2019 Breast
ESMO Breast Cancer 2019: international survey raises questions on the future of HER2 testing

Video

View all videos

2 May 2019 Journal Articles
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety

Video

View all videos

Features

Stay up to date

Upcoming event

ESMO Breast Cancer 2019 – annual congress

May 2, 2019 – May 4, 2019

Berlin, Germany

View all

Upcoming event

American Society of Clinical Oncology (ASCO) annual meeting

May 31, 2019 – June 4, 2019

IL, USA

View all

Tweets

Oncology Central @OncologyCentral·

A recent study has used #CRISPR to identify #genefusions that are essential for cancer cell survival, these could present novel drug targets for the future. Click the image below for the full news story: https://t.co/OzFBrnxFsN

View all

Jobs

Connecting talent with opportunity. View our featured jobs

View all

Our mission statement

At Oncology Central we are dedicated to advancing oncology by publishing trusted, engaging and insightful resources for the global oncology community.

Learn more

Tumor-targeting protein could advance personalized cancer therapy

Novel drug could be world’s first treatment for a pediatric brain cancer

ESMO Breast Cancer 2019: should HER2-positive breast cancer treatment de-escalation be personalized?

ESMO Breast Cancer 2019: international survey raises questions on the future of HER2 testing

Spotlight survey on organoids on oncology

Pembrolizumab for small-cell lung cancer: an interview with Hyun Cheol Chung

Pharma, President, Patients: the cancer cost conundrum

How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive NSCLC?

Enhancing and improving CAR-T cell therapy: an interview with Bruce Levine

I-O Optimise: a multinational program providing real-world insights into lung cancer management

Scientific survival suggestions: V. Craig Jordan’s top 10 tips

Unlocking the power of the cancer genome: an interview with Phil Febbo, Illumina Inc.

Colorectal cancer screening age to be lowered to 50 in England

Video

Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety

Video

Login

Latest news

Tumor-targeting protein could advance personalized cancer therapy

Novel drug could be world’s first treatment for a pediatric brain cancer

ESMO Breast Cancer 2019: should HER2-positive breast cancer treatment de-escalation be personalized?

ESMO Breast Cancer 2019: international survey raises questions on the future of HER2 testing

Featured articles

Spotlight survey on organoids on oncology

Pembrolizumab for small-cell lung cancer: an interview with Hyun Cheol Chung

Pharma, President, Patients: the cancer cost conundrum

How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive NSCLC?

Enhancing and improving CAR-T cell therapy: an interview with Bruce Levine

I-O Optimise: a multinational program providing real-world insights into lung cancer management

Scientific survival suggestions: V. Craig Jordan’s top 10 tips

Unlocking the power of the cancer genome: an interview with Phil Febbo, Illumina Inc.

Colorectal cancer screening age to be lowered to 50 in England

Video

Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety

Video

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

HTX-019 2-min injection shows promise as an alternative method of administration to prevent CINV

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Emerging treatment options for pancreatic cancer with Thomas Seufferlein

Tamoxifen, SERMs and sustainable medicine

Seven challenges in immuno-oncology

Features

Interviews

Spotlights

Journal articles

Stay up to date

Oncology Central Newsletter